Anmelden Kostenlos registrieren

Last updated: 22 March 2024 at 5:12pm EST

Caroline Loewy Net Worth




The estimated Net Worth of Caroline M Loewy is at least $320 Tausend dollars as of 19 May 2023. Ms. Loewy owns over 3,750 units of Cymabay Therapeutics Inc stock worth over $121,800 and over the last 16 years she sold CBAY stock worth over $0. In addition, she makes $198,493 as Independent Director at Cymabay Therapeutics Inc.

Ms. Loewy CBAY stock SEC Form 4 insiders trading

Caroline has made over 1 trades of the Cymabay Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she exercised 3,750 units of CBAY stock worth $121,800 on 19 May 2023.

The largest trade she's ever made was exercising 3,750 units of Cymabay Therapeutics Inc stock on 19 May 2023 worth over $121,800. On average, Caroline trades about 139 units every 0 days since 2008. As of 19 May 2023 she still owns at least 3,750 units of Cymabay Therapeutics Inc stock.

You can see the complete history of Ms. Loewy stock trades at the bottom of the page.





Caroline Loewy biography

Caroline Loewy is Independent Director of the Company. Ms. Loewy is a biopharmaceutical and financial executive with over 25 years of experience in the field. She currently provides strategic advisory services for biopharmaceutical companies, primarily in the role of board member. Ms. Loewy is currently a member of the board of directors of PhaseBio Pharmaceuticals, Inc. and Aptose Biosciences Inc., each since 2018. Previously Ms. Loewy was a Co-Founder and served as the Chief Business Officer and Chief Financial Officer of Achieve Life Sciences, a biopharmaceutical company (acquired by OncoGenex Pharmaceuticals, Inc. in 2017), from 2015 to 2017. Ms. Loewy has previously held the position of Chief Financial Officer of both public and private biopharmaceutical companies including Tobira Therapeutics (acquired by Allergan Inc. in 2016) from 2012 to 2014, Corcept Therapeutics from 2008 to 2011, and Poniard Pharmaceuticals from 2006 to 2008. Prior to her roles in company management, Ms. Loewy spent 11 years as a senior biotechnology equity research analyst at Morgan Stanley and Prudential Securities. Ms. Loewy has leveraged her experience in the medical arena and financial expertise to benefit those affected by rare disease. She is a founding board member of the Global Genes Project, one of the leading rare disease patient advocacy organizations in the world, and is a member of the National Advisory Council of the Translational Genomics Research Institute (TGen) Center for Rare Childhood Disorders. Ms. Loewy is also a founding board member of the KCNQ2 Cure Alliance, promoting education and research into the rare disorder affecting her son. Ms. Loewy holds a B.A. from the University of California, Berkeley, and a MBA/MS from Carnegie Mellon University. Because of her more than 25 years of experience in the biopharmaceutical industry and financial expertise as a chief financial officer, as well as her extensive and valuable experience in providing strategic advisory services.

What is the salary of Caroline Loewy?

As the Independent Director of Cymabay Therapeutics Inc, the total compensation of Caroline Loewy at Cymabay Therapeutics Inc is $198,493. There are 10 executives at Cymabay Therapeutics Inc getting paid more, with Sujal Shah having the highest compensation of $2,556,470.



How old is Caroline Loewy?

Caroline Loewy is 54, she's been the Independent Director of Cymabay Therapeutics Inc since 2016. There are 7 older and 9 younger executives at Cymabay Therapeutics Inc. The oldest executive at Cymabay Therapeutics Inc is Robert Wills, 66, who is the Independent Chairman of the Board.

What's Caroline Loewy's mailing address?

Caroline's mailing address filed with the SEC is C/O CYMABAY THERAPEUTICS, INC., 7601 DUMBARTON CIRCLE, FREMONT, CA, 94555.

Insiders trading at Cymabay Therapeutics Inc

Over the last 10 years, insiders at Cymabay Therapeutics Inc have traded over $17,635,452 worth of Cymabay Therapeutics Inc stock and bought 2,170,647 units worth $6,725,086 . The most active insiders traders include Capital Advisors Llc Aghaza..., Kurt Von Emster und Carl Goldfischer. On average, Cymabay Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,796,241. The most recent stock trade was executed by Sujal Shah on 13 March 2024, trading 139,119 units of CBAY stock currently worth $656,642.



What does Cymabay Therapeutics Inc do?

cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.



What does Cymabay Therapeutics Inc's logo look like?

Cymabay Therapeutics Inc logo

Complete history of Ms. Loewy stock trades at Aptose Biosciences Inc, Corcept Therapeutics Inc, Cymabay Therapeutics Inc, Zogenix Inc und PhaseBio Pharmaceuticals

Datum
#
Unternehmen
 Insider
Trans.
Transaktion
 Anzahl der Aktien Preis je Aktie Gesamtpreis Anzahl der Aktien nach Quelle
19 May 2023 PHAS PhaseBio Pharmaceuticals, Inc. Caroline M Loewy
Direktor
 Optionausübung 3,750 $0.04 $150
19 May 2023
3,750 ↗


Cymabay Therapeutics Inc executives and stock owners

Cymabay Therapeutics Inc executives and other stock owners filed with the SEC include: